Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Randomized Control Trials in the Pre-Delta Era: A Systematic Review and Network Meta-Analysis

Oh, SuA, Purja, Sujata, Shin, Hocheol, Kim, Minseo, Park, Seoyeon, Kronbichler, Andreas, Smith, Lee ORCID: https://orcid.org/0000-0002-5340-9833, Eisenhut, Michael, Shin, Jae Il and Kim, Eunyoung (2022) Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Randomized Control Trials in the Pre-Delta Era: A Systematic Review and Network Meta-Analysis. Vaccines. ISSN 2076-393X

Preview	Text Published Version Available under the following license: Creative Commons Attribution. Download (3MB) | Preview
	Text Accepted Version Restricted to Repository staff only Available under the following license: Creative Commons Attribution Non-commercial No Derivatives. Download (1MB)
	Text (Word Version) Accepted Version Restricted to Repository staff only Available under the following license: Creative Commons Attribution Non-commercial No Derivatives. Download (3MB)

Abstract

The most effective method of limiting the coronavirus disease pandemic of 2019 (COVID-19) is vaccination. For the determination of the comparative efficacy and safety of COVID-19 vaccines and their platforms during the pre-Delta era, a systematic review and network meta-analysis was conducted. The MEDLINE, Embase, and MedRxiv databases were searched, and the gray literature was manually searched up to 8 July 2021. The review includes the phase II and III randomized controlled trials (RCTs) that assessed the efficacy, immunogenicity, and safety of the COVID-19 vaccines. The network meta-analysis used a Bayesian model and used the surface under the cumulative ranking to rank the comparisons between the vaccines. All included studies were quality appraised according to their design, and the heterogeneity of the analyses was assessed using I2. In terms of vaccine efficacy, the mRNA-1273 vaccine ranked the highest, and the CoronaVac vaccine ranked the lowest. The mRNA-1273 ranked the highest for neutralizing antibody responses to live SARS-CoV-2. The WIV04 vaccine was associated with the lowest incidence of both local and systemic adverse reactions. All studies except one had a low to moderate risk of bias. The mRNA platform vaccines showed higher efficacy and more adverse reactions than the other vaccines

Item Type:	Journal Article
Keywords:	COVID-19, SARS-CoV-2, Network Meta-Analysis
Faculty:	COVID-19 Research Collection Faculty of Science & Engineering
SWORD Depositor:	Symplectic User
Depositing User:	Symplectic User
Date Deposited:	16 Sep 2022 10:52
Last Modified:	24 Nov 2022 09:12
URI:	https://arro.anglia.ac.uk/id/eprint/707923

Actions (login required)

Edit Item